Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

371.18
Delayed Data
As of Feb 17
 -1.84 / -0.49%
Today’s Change
325.35
Today|||52-Week Range
452.96
+1.11%
Year-to-Date
Amgen Shows a Bullish Breakout
Feb 16 / TheStreet.com - Paid Partner Content
3 Beaten-Down Stocks Ready to Bounce Back
Feb 10 / MotleyFool.com - Paid Partner Content
Bullish Momentum for Regeneron
Feb 15 / TheStreet.com - Paid Partner Content
Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak
Feb 09 / Zacks.com - Paid Partner Content
Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More
Feb 15 / Zacks.com - Paid Partner Content
Regeneron (REGN) Q4 Earnings Misses Estimates
Feb 09 / Zacks.com - Paid Partner Content
Amgen Looking to Broaden Leukemia Drug Blincyto's Label
Feb 15 / Zacks.com - Paid Partner Content
Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?
Feb 08 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Present...
Feb 15 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigat...
Feb 08 / Zacks.com - Paid Partner Content
A Big Corporate Tax Boost for Big Spenders?
Feb 14 / TheStreet.com - Paid Partner Content